Exelixis Gestion

Gestion contrôle des critères 3/4

Le PDG Exelixis est Mike Morrissey, nommé en Jul2010, a un mandat de 14.33 ans. La rémunération annuelle totale est $ 16.42M, composée du salaire de 7.3% et des bonus 92.7%, y compris les actions et options de la société. détient directement 0.56% des actions de la société, d'une valeur de € 54.88M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 8.5 ans et 7.4 ans.

Informations clés

Mike Morrissey

Directeur général

US$16.4m

Rémunération totale

Pourcentage du salaire du PDG	7.3%
Durée du mandat du directeur général	14.3yrs
Propriété du PDG	0.6%
Durée moyenne d'occupation des postes de direction	8.5yrs
Durée moyenne du mandat des membres du conseil d'administration	7.4yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Mike Morrissey a-t-elle évolué par rapport aux bénéfices de Exelixis?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2024	n/a	n/a	US$467m
Jun 30 2024	n/a	n/a	US$350m
Mar 31 2024	n/a	n/a	US$205m
Dec 31 2023	n/a	n/a	US$208m
Sep 30 2023	n/a	n/a	US$92m
Jun 30 2023	n/a	n/a	US$164m
Mar 31 2023	n/a	n/a	US$154m
Dec 31 2022	US$17m	US$1m	US$182m
Sep 30 2022	n/a	n/a	US$308m
Jun 30 2022	n/a	n/a	US$273m
Mar 31 2022	n/a	n/a	US$298m
Dec 31 2021	US$8m	US$1m	US$231m
Sep 30 2021	n/a	n/a	US$164m
Jun 30 2021	n/a	n/a	US$94m
Mar 31 2021	n/a	n/a	US$65m
Dec 31 2020	n/a	n/a	US$112m
Sep 30 2020	n/a	n/a	US$152m
Jun 30 2020	n/a	n/a	US$282m
Mar 31 2020	n/a	n/a	US$294m
Dec 31 2019	n/a	n/a	US$321m
Sep 30 2019	n/a	n/a	US$612m
Jun 30 2019	n/a	n/a	US$642m
Mar 31 2019	n/a	n/a	US$650m
Dec 31 2018	n/a	n/a	US$690m
Sep 30 2018	n/a	n/a	US$368m
Jun 30 2018	n/a	n/a	US$323m
Mar 31 2018	n/a	n/a	US$253m
Dec 31 2017	n/a	n/a	US$154m

Rémunération vs marché: La rémunération totale de Mike ($USD 16.42M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché German ($USD 4.78M ).

Rémunération et revenus: La rémunération de Mike a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Mike Morrissey (63 yo)

14.3yrs

Titularisation

US$16,423,307

Compensation

Dr. Michael M. Morrissey, Ph.D. also known as Mike, serves as Independent Director at XW Laboratories Inc. Dr. Morrissey serves as Independent Chairman of the Board at Vera Therapeutics, Inc since May 24,...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Stelios Papadopoulos	Co-Founder & Chair of the Board	29.9yrs	US$519.97k	0.43% € 42.4m
Michael Morrissey	CEO, President & Director	14.3yrs	US$16.42m	0.56% € 54.9m
Christopher Senner	Executive VP & CFO	9.3yrs	US$4.95m	0.16% € 16.0m
Dana Aftab	Executive VP of Discovery and Translational Research & Chief Scientific Officer	1.9yrs	US$5.65m	0.080% € 7.8m
Jeffrey Hessekiel	Executive VP & General Counsel	10.8yrs	US$4.56m	0.11% € 10.6m
Amy Peterson	Executive VP	1.3yrs	US$7.38m	0.10% € 10.1m
Susan Hubbard	Executive Vice President of Public Affairs & Investor Relations	7.9yrs	pas de données	pas de données
Tony Redmond	Senior Vice President of Human Resources	less than a year	pas de données	pas de données
Anne Champsaur	Senior Vice President of Drug Safety	9.6yrs	pas de données	pas de données
William Berg	Senior Vice President of Medical Affairs	9.2yrs	pas de données	pas de données
Patrick Haley	Executive Vice President of Commercial	7.9yrs	US$4.65m	0.039% € 3.8m
Stefan Krauss	VP & Head of Business Development	no data	pas de données	pas de données

8.5yrs

Durée moyenne de l'emploi

57yo

Âge moyen

Gestion expérimentée: L'équipe dirigeante de EX9 est chevronnée et expérimentée (8.5 années d'ancienneté moyenne).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Stelios Papadopoulos	Co-Founder & Chair of the Board	29.9yrs	US$519.97k	0.43% € 42.4m
Michael Morrissey	CEO, President & Director	14.3yrs	US$16.42m	0.56% € 54.9m
Jack Wyszomierski	Independent Director	20.8yrs	US$490.97k	0.12% € 11.3m
George Poste	Independent Director	20.3yrs	US$482.22k	0.053% € 5.1m
Charles Sawyers	Member of the Scientific Advisory Board	no data	pas de données	pas de données
Ronald Evans	Member of the Scientific Advisory Board	no data	pas de données	pas de données
Sue Eckhardt	Independent Director	less than a year	pas de données	0% € 0
Mary Beckerle	Independent Director	less than a year	pas de données	0% € 0
Julie Smith	Independent Director	8.2yrs	US$490.92k	0.00027% € 26.4k
Maria Freire	Independent Director	6.6yrs	US$488.72k	0.025% € 2.5m
Robert Oliver	Independent Director	1.5yrs	US$717.44k	0.0016% € 155.3k
Tomas Heyman	Independent Director	1.5yrs	US$716.19k	0.0016% € 155.3k

7.4yrs

Durée moyenne de l'emploi

68yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de EX9 sont considérés comme expérimentés (ancienneté moyenne 7.4 ans).

Exelixis Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

Independent Director recently sold €940k worth of stock

Independent Director recently sold €831k worth of stock

Independent Director recently sold €531k worth of stock

Exelixis, Inc., Annual General Meeting, May 30, 2024

Executive Vice President of Commercial recently sold €932k worth of stock

Exelixis, Inc. Announces Vicki L. Goodman Concludes Her Service as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer

Recent updates

Independent Director recently sold €940k worth of stock

Investor sentiment improves as stock rises 23%

Exelixis, Inc. Reports Impairment of Long-Lived Assets for the Third Quarter Ended September 30, 2024

Exelixis, Inc. to Report Q3, 2024 Results on Oct 29, 2024

Exelixis, Inc Announces Final Results from Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of Medicine

Independent Director recently sold €831k worth of stock

Exelixis, Inc. Announces Initiation of Phase 1 Clinical Trial Evaluating XB010 in Patients with Advanced Solid Tumors

Second quarter 2024 earnings released: EPS: US$0.78 (vs US$0.25 in 2Q 2023)

Exelixis, Inc. (NasdaqGS:EXEL) announces an Equity Buyback for $500 million worth of its shares.

Exelixis, Inc. Announces U.S. Food and Drug Administration Accepted the Supplemental New Drug Application for Cabozantinib for Patients with Advanced Neuroendocrine Tumors

Exelixis, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Independent Director recently sold €531k worth of stock

Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA

First quarter 2024 earnings released: EPS: US$0.12 (vs US$0.12 in 1Q 2023)

Exelixis, Inc. Reaffirms Earnings Guidance for the Year 2024

Exelixis, Inc., Annual General Meeting, May 30, 2024

Exelixis, Inc. to Report Q1, 2024 Results on Apr 30, 2024

Executive Vice President of Commercial recently sold €932k worth of stock

Full year 2023 earnings released: EPS: US$0.65 (vs US$0.57 in FY 2022)

Exelixis, Inc. Provides Earnings Guidance for the for Fiscal Year 2024

Exelixis, Inc. Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024

Bristol Myers Squibb and Exelixis, Inc. Announce Four-Year Follow-Up Results from the CheckMate -9ER Trial Evaluating Opdivo (cabozantinib)

Exelixis, Inc. (NasdaqGS:EXEL) announces an Equity Buyback for $450 million worth of its shares.

Exelixis, Inc. (NasdaqGS:EXEL) announces an Equity Buyback for $450 million worth of its shares.

Exelixis Announces Initiation of the Stellar-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck Cancer

Exelixis, Inc. Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023

Third quarter 2023 earnings released: EPS: US$0.003 (vs US$0.23 in 3Q 2022)

Exelixis, Inc. Announces Detailed Results from Phase 3 Cabinet Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023

Exelixis, Inc. to Report Q3, 2023 Results on Nov 01, 2023

Exelixis, Inc. Announces Positive Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors

Exelixis, Inc. Announces Vicki L. Goodman Concludes Her Service as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer

Exelixis, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Exelixis, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Exelixis, Inc. Elects Dave Johnson to its Board of Directors

First quarter 2023 earnings released: EPS: US$0.12 (vs US$0.21 in 1Q 2022)

Exelixis, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Exelixis Announces Departure of Lance Willsey, M.D. From Board of Directors

Bristol-Myers Squibb Company and Exelixis, Inc. Announces Opdivo in Combination with Cabometyx Shows Durable Survival with over Three Years of Follow-Up in the Checkmate -9Er Trial in First-Line Advanced Renal Cell Carcinoma

Exelixis, Inc. and Sairopa B.V. Announces US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with Advanced Solid Tumors

Full year 2022 earnings released: EPS: US$0.57 (vs US$0.73 in FY 2021)

Exelixis, Inc. Provides Revenue Guidance for Fiscal Year 2023

Exelixis, Inc. to Report Q4, 2022 Results on Feb 07, 2023

Exelixis, Inc. Provides Revenue Guidance for Full Year 2023

Exelixis, Inc. Announces Initiation of the STELLAR-304 Phase 3 Pivotal Trial Evaluating Zanzalintinib in Patients with Advanced Non-Clear Cell Kidney Cancer

Exelixis, Inc. Announces Board Appointments

Exelixis, Inc. Provides Update on Phase 3 CONTACT-01 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with Immunotherapy and Chemotherapy

Exelixis, Inc. Announces Initial Dose-Escalation Results from the First-In-Human Phase 1 Trial Evaluating XL102 in Patients with Advanced Solid Tumors at SABCS 2022

Insufficient new directors

Third quarter 2022 earnings released: EPS: US$0.23 (vs US$0.12 in 3Q 2021)

Exelixis, Inc. Provides Revenue Guidance for 2022

Exelixis, Inc. Announces Promising Initial Dose-Escalation Results from the First-In-Human Phase 1 JEWEL-101 Trial Evaluating XB002 in Patients with Advanced Solid Tumors at ENA 2022

Exelixis, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Exelixis, Inc. Announces Dose-Escalation Results from the Phase 1 STELLAR-001 Trial Evaluating XL092 Alone and in Combination with an Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ESMO 2022

Exelixis, Inc. Announces Detailed Results from Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer at ESMO 2022

Second quarter 2022 earnings released: EPS: US$0.22 (vs US$0.31 in 2Q 2021)

Exelixis, Inc. Maintains Earnings Guidance for the Fiscal Year 2022

Exelixis, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Exelixis, Inc. Announces COSMIC-313 Met Its Primary Endpoint

Investor sentiment improved over the past week

Exelixis Announces Initiation of the STELLAR-303 Phase 3 Pivotal Trial Evaluating XL092 in Patients with Metastatic Colorectal Cancer

Executive Vice President of Commercial recently sold €320k worth of stock

Exelixis, Inc. Announces Results from Phase 2 Trial of Cabozantinib in Combination with Pembrolizumab in Patients

Exelixis, Inc. Provides Earnings Guidance for the Fiscal Year 2022

First quarter 2022 earnings released: EPS: US$0.21 (vs US$0.005 in 1Q 2021)

Insufficient new directors

Exelixis, Inc. Announces Initiation of First-In-Human Phase 1 Trial Evaluating XL114 Monotherapy in Patients with Non-Hodgkin’s Lymphoma

Exelixis, Inc. Announces Charles Cohen to Retire from Board of Directors

Co-Founder & Independent Chairman recently sold €1.5m worth of stock

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat